Introduction {#S1}
============

Cutaneous squamous cell carcinoma (SCC), the second most frequent skin cancer, arises from interfollicular epidermal keratinocytes. Transformed malignant cells can proliferate in the epidermis as in situ SCC, eventually cross the basement membrane and enter the dermis to form invasive SCC. Invasion to the dermis is a critical event, since cancer cells are allowed to access lymphatic and to a lesser degree blood vessels, which may result in metastasis. The American Joint Committee on Cancer, in fact, added tumor depth (\>2-mm thickness or Clark level ≥IV) as a high-risk feature of SCC ([@R6]). Although usually curable by resection, SCC accounts for the majority of approximately 10,000 deaths from non-melanoma skin cancer in the United States each year ([@R39]).

Cancer invasion can be mediated by several processes including degradation of extracellular matrix (ECM) and growth and migration of tumor cells into surrounding stromal regions. Thus, studying the expression and regulation of tumor growth factors and proteolytic molecules within a tissue is important. Gene expression analysis, such as cDNA microarray analysis, has been applied to many cancer types including cutaneous SCC ([@R5]; [@R22]; [@R17]; [@R9]; [@R12]; [@R23]). These prior studies identified numerous genes that might be involved in SCC pathogenesis. For example, we reported that matrix metallopeptidases (MMPs) including *MMP1, MMP10*, and *MMP13* were selectively expressed in SCC but not in psoriasis, a benign inflammatory skin disease characterized by epidermal hyperproliferation, but without invasion into the dermis by keratinocytes ([@R9]). This suggests the potential importance of these MMPs in SCC progression.

Cytokines also have significant functions in tumor biology. Th1 cytokines, such as IFN-γ, have been thought to possess anti-tumor properties, whereas Th2 cytokines, such as IL-4, have primarily pro-tumor activity. Recent studies, however, reveal that the cytokines, such as IFN-γ, possess both anti- and pro-tumor activities depending on the tumor types as well as the tumor microenvironment ([@R40]). IL-24, also known as melanoma differentiation associated gene-7 (mda-7), is a member of the IL-10 family of cytokines. It was initially found as a growth inhibitor of melanoma ([@R16]). Mounting evidence established a role of IL-24 in inducing apoptosis and cell death in many solid cancers including melanoma as well as epithelial carcinomas of various organs ([@R4]). However, phase I clinical study using an adenovirus containing IL-24/mda-7 construct (Ad.IL24/mda-7, INGN241) was not able to control tumor growth of a penile, and a head and neck SCC ([@R3]). IL-24 is known to be highly produced in psoriasis lesional skin ([@R30]). In addition, IL-24 was as potent as IL-22 to induce keratinocytic hyperplasia in a reconstituted human epidermis culture model ([@R31]). It was thus speculated that IL-24 might have distinct functions in cutaneous SCC growth as opposed to anti-tumor functions established in other cancer types.

Cancer cells may change their phenotypes along with tumor progression, i.e. a switch of E-cadherin to N-cadherin expression ([@R11]) and an epithelial-to-mesenchymal transition in invading tumor cells ([@R37]). Cells at the invading front might, thus, be genomically distinct from bulk tumor cells. Therefore, we used laser capture microdissection (LCM) in order to collect subpopulations of SCC cells from human skin tissue. We generated the invasion signature gene set of cutaneous SCC, which is a set of genes that were differentially regulated in SCC invasive nests, but not in actinic keratosis (AK) or in situ SCC regions, compared to normal epidermis. We identified significant up-regulation of *IL-24* and *MMP7* mRNA in the invading front of cutaneous SCC. Molecular interaction of these two molecules and their potential role in SCC progression are discussed in this study.

Results {#S2}
=======

LCM combined with cDNA microarray analysis provides specific gene expression profiles for various stages of SCC progression {#S3}
---------------------------------------------------------------------------------------------------------------------------

Tumor debulking samples were obtained during Mohs micrographic surgery for SCC. Three transformed epidermal regions in this study that represent the transition to invasive SCC were defined as follows: 1) actinic keratosis (AK atrophic type), regions of severe dysplasia at the basal layer of atrophic epidermis with solar elastosis in dermis, 2) in situ SCC, tumor regions with transformed keratinocytes throughout the entire epidermis that have not crossed the basement membrane, and 3) invasive SCC, tumor nests that have invaded the dermis and disconnected from the bulk tumor mass ([Figure 1a](#F1){ref-type="fig"}). There were 724 up- and 820 down-regulated probe-sets in AK, 1042 up- and 1200 down-regulated probe-sets in in situ SCC, and 1325 up- and 1461 down-regulated probe-sets in invasive SCC compared to microdissected normal epidermis \[fold change (FCH)\>3.0 and false discovery rate (FDR)\<0.05, [Figure 1a](#F1){ref-type="fig"}\]. A Venn-diagram demonstrated 1083 (503 up- and 580 down-regulated) commonly regulated probe-sets among the three regions, including *S100As, KRT6*, and *serpins* ([Figure 1 b--c](#F1){ref-type="fig"}). A group of genes that was selectively regulated in invasive SCC, but not in dysplasia or in situ SCC, was of particular interest as these genes might have significant roles in SCC invasion to the dermis. This consists of 383 up- and 354 down-regulated probe-sets and these genes were designated as invasion signature genes ([Table S1](#SD1){ref-type="supplementary-material"}). The complete gene lists comparing each region to microdissected normal epidermis are found in [Tables S2--S4](#SD1){ref-type="supplementary-material"}.

The invasion signature gene set characterized the tumor nests at the invasion front {#S4}
-----------------------------------------------------------------------------------

[Table 1](#T1){ref-type="table"} shows selected up- and down-regulated invasion signature genes. Genes encoding proteolytic molecules, such as *MMPs* and *PLAU*, were highly up-regulated. A cell adhesion molecule *LAMC2* was also up-regulated. The expression of PDPN in cutaneous SCC was reported previously by qRT-PCR and by immunohistochemistry ([@R21]; [@R34]). In contrast, melanocyte-related genes such as *TYRP1, DCT*, and *KIT*, as well as keratinocyte differentiation markers including *FLG, LOR*, and *LCE2B*, were down-regulated. Ingenuity pathway analysis linked 28 canonical pathways to the SCC invasion signature gene set ([Table S5](#SD1){ref-type="supplementary-material"}, Fisher's exact test, *p*\<0.05). The most significant pathway was Leukocyte extravasation signaling (*p*=9.56×10^−4^), followed by Aryl hydrocarbon receptor signaling (*p*=1.46×10^−3^), and Hypoxia-inducible factor 1α signaling (*p*=1.54×10^−3^).

Regional expression of MMPs in the SCC tissue was mapped using pre-amplification quantitative RT-PCR {#S5}
----------------------------------------------------------------------------------------------------

The expression of MMPs in SCC invasion nests was further investigated, as three of the top 6 genes in the invasion signature gene set were MMPs (*MMP12, -3*, and *-13*) and MMPs are critical for degrading the ECM surrounding tumor nests. Eleven MMPs were detected as differentially expressed probe-sets along with SCC progression by microarray analysis ([Table 2](#T2){ref-type="table"}). The expression of *MMP9, -11*, and *-14* was increased even in AK. The expression of *MMP1, -2*, and *-10* started to elevate in in situ SCC, and further increased in invasive SCC by approximately 2 to 7 fold compared to in situ SCC. *MMP1* was the most abundant MMP in invasive SCC with a FCH=107.82, followed by *MMP10* with a FCH=48.35. The expression of *MMP3, -7, -12, -13*, and *-17* was selective for invasive SCC. The regional expression difference of all 23 known human *MMPs* was further tested using the same RNA used for microarray analysis by a more sensitive RT-PCR detection. A heat map clearly showed the increase of expression of multiple MMPs towards invasive SCC ([Figure 2a](#F2){ref-type="fig"}). 12 out of 23 genes tested had significant difference among the four keratinocytic regions (*p*\<0.05, [Figure 2b--e](#F2){ref-type="fig"} and [Figure S1](#SD1){ref-type="supplementary-material"}). Eleven of those 12 genes were up-regulated in cancer regions compared to normal epidermis or AK. The expression of *MMP28* was lower in in situ SCC than in normal epidermis. This was consistent with a previous report showing the specific expression of MMP28 in proliferating keratinocytes during wound healing, but not in SCC ([@R32]). mRNA of *MMP8, -20*, -23B, *-26, and -27* was rarely detected in any keratinocytic regions tested ([Figure S1](#SD1){ref-type="supplementary-material"}). In addition, proportional odds model identified 14 MMPs as statistically significant (\* in [Figure 2a](#F2){ref-type="fig"}, *p* values in [Table S6](#SD1){ref-type="supplementary-material"}). This indicates that gene expression of those MMPs increases the odds of being in a phenotype of higher degree of malignancy. The results of cDNA microarray and pre-amplification RT-PCR were positively correlated as evidenced by Pearson's r=0.788 (*p*\<0.0001), when the 11 genes detected in both methods were compared ([Figure S2](#SD1){ref-type="supplementary-material"}).

Altered protein expression of the selected genes was confirmed by immunohistochemistry {#S6}
--------------------------------------------------------------------------------------

Immunohistochemistry was performed in order to confirm the altered protein expression of the corresponding genes within tissue. MMP1, the most up-regulated MMP on our gene list, strongly stained both SCC tumor nests and the interstitial region surrounding tumor nests ([Figure 2f--g](#F2){ref-type="fig"}). Staining of MMP3 and MMP7 was selective in the invading cancer cells, but not in the epidermis of normal skin or the epidermis above the tumor nests ([Figure 2h--k](#F2){ref-type="fig"}), thus confirming the specificity and gradual increase of the mRNA expression in tumor nests. MMP10 strongly stained tumor nests in the dermis, but it also stained the basal layer of keratinocytes in normal skin ([Figure 2l--m](#F2){ref-type="fig"}). These genomic and protein data provide the localization of MMPs within the cutaneous SCC tissues.

IL-24 was increased in SCC invasion front and up-regulated the expression of MMP7 *in SCC cells in vitro* {#S7}
---------------------------------------------------------------------------------------------------------

*IL-24* was up-regulated in our SCC invasion signature gene set ([Table 1a](#T1){ref-type="table"}). mRNA and protein expression of *IL-24* as well as its receptor subunits (*IL-20R1, IL-20R2*, and *IL-22R1*) within the tissues was confirmed. The expression of *IL-24* mRNA was detected only in in situ SCC and invasive SCC, but not in AK ([Figure 3a](#F3){ref-type="fig"}). An IL-24 antibody detected signals in SCC tumor nests, but not normal skin ([Figure 3b--c](#F3){ref-type="fig"}). mRNA of the three receptor subunits was constitutively expressed in all regions, although *IL20R1* was slightly decreased in invasive SCC ([Figure 3d--f](#F3){ref-type="fig"}). It has been reported that some cytokines, including TGF-α, enhance the expression of IL-24 in HaCaT cells as well as normal human epidermal keratinocytes ([@R26]). The expression of *IL-24* mRNA in two human cutaneous SCC cell lines was thus investigated \[see detailed descriptions of these cells in the [supplemental materials and methods](#SD1){ref-type="supplementary-material"} (SMM)\]. SCC13 cells ([@R29]) constitutively expressed *IL-24* mRNA without addition of any cytokines. This expression was further increased by stimulation with TGF-α, TNF-α, and IFN-γ ([Figure 3g](#F3){ref-type="fig"}). A431 cells, another SCC cell line ([@R7]; [@R27]), did not express *IL-24* regardless of the stimuli (data not shown). IL-24 utilizes the same receptors to activate cells as IL-20 ([@R33]), and IL-20 has been reported to up-regulate the expression of *MMP7* in HaCaT cells ([@R38]). Hence, we hypothesized that IL-24 might play a role in up-regulating the expression of *MMP7* mRNA in SCC. *MMP7* mRNA in A431 or HaCaT cells was increased when cultured with 40ng/ml or 100ng/ml of IL-24, or 100ng/ml of IL20 for 24 hours ([Figure 3h--i](#F3){ref-type="fig"}). *MMP7* mRNA was not increased in SCC13 cells with the addition of IL20 or IL24 ([Figure 3j](#F3){ref-type="fig"}), although SCC13 cells expressed *IL-24* mRNA constitutively. This might be in part explained by significantly lower expression of the IL-24 receptor subunits in SCC13 cells compared to others ([Figure S3](#SD1){ref-type="supplementary-material"}). Nevertheless, these data suggest a role of IL-24 in enhancing the expression of *MMP7* in SCC cells, which may contribute to cancer progression.

Blocking of MMP7 by a specific antibody significantly delayed the migration of A431 cells {#S8}
-----------------------------------------------------------------------------------------

Finally, the function of MMP7 in A431 cells was examined using a scratch assay. A431 cells were selected since this cell line expresses approximately 50-fold higher *MMP7* mRNA than the other two cell lines tested ([Figure 3h--j](#F3){ref-type="fig"}). A scratch was made when A431 cells reached 90% confluence, and they were maintained in the 0.1%FBS-containing media with or without an MMP7 antibody (MMP7Ab). The MMP7Ab used in this experiment was shown to block activity of MMP7 ([@R15]). [Figure 4a--d](#F4){ref-type="fig"} show the gap between cells after a 36 hour treatment with PBS alone (a) or different concentrations of the MMP7Ab \[20ng/ml (b), 200ng/ml (c), and 2000ng/ml (d)\]. The effect of blocking MMP7 was evaluated by calculating a percent confluence for each condition at each time point. The MMP7Ab significantly delayed the migration of A431 cells at a concentration of 2000ng/ml compared to the other conditions ([Figure 4e](#F4){ref-type="fig"}). This was also true after a 24 hour treatment with the MMP7Ab treatment at 2000ng/ml compared to PBS and 20ng/ml MMP7Ab ([Figure 4f](#F4){ref-type="fig"}). A similar effect was observed when the A431 cells were maintained in media containing 10%FBS ([Figure S4](#SD1){ref-type="supplementary-material"}). These results suggest the involvement of MMP7 in the migration of cutaneous SCC.

Discussion {#S9}
==========

Previous studies including our own have examined gene expression profiling of cutaneous SCC using total RNA extracted from full thickness tumor tissues ([@R5]; [@R22]; [@R17]; [@R9]; [@R12]; [@R23]). To our knowledge, no studies combining LCM and cDNA microarray analysis on cutaneous SCC have been published. Our current study confirmed many genes of previous findings, i.e., the enhanced expression of epidermal differentiation complex genes, such as S100As, SPRRs, IVL, and LCE3D. Hudson *et al*. proposed the expression of *KRT13* as a marker of SCC. In this study, we found that *KRT13* is specific to in situ and invasive SCC, but not AK. Thus, our study is unique in localizing hundreds of gene products to different stages of tumor progression *in vivo* by combining LCM and cDNA microarray analysis. This helps to identify molecular interactions that may happen in focal regions of SCC. One such example is the focal regulation of MMP7 by IL-24 cytokine.

IL-24 has been shown to induce apoptosis and cell death in many solid cancers ([@R4]). Its expression has been inversely correlated with lymph node metastasis or overall survival in some cancers ([@R14]; [@R24]; [@R2]). However, a phase I clinical study of intra-tumoral injections of Ad.IL24/mda-7 resulted in progressive disease in two cases of SCC ([@R3]). New nodules arose around the periphery of the skin nodule of penile SCC after treatment. These results may thus suggest a putative pro-oncogenic function of IL-24 in SCC growth. Our findings may support this notion. We found that IL-24 was significantly overexpressed at the invasion nest of SCC. *IL-24* mRNA was constitutively expressed in SCC13 cells and this was further enhanced by culturing with TNF-α, TGF-α, and IFN-γ. The cellular source of IL-24 may, however, be more complicated within the SCC microenvironment. Th2 cells and macrophages as well as melanocytes produce IL-24 ([@R25]), and those cells reside in the SCC microenvironment. In fact, *IL-24* mRNA was also up-regulated in inflammatory infiltrating cell regions surrounding tumor nests compared to normal reticular dermis ([@R1]). We thus concluded that IL-24 can be derived from multiple cell types including cancer cells within the SCC microenvironment. We have previously reported that IL-24 promoted neither proliferation nor apoptosis of A431 cells when cultured in a starvation condition (0.1%FBS) ([@R41]). Instead, we report herein a function of IL-24 in increasing the expression of *MMP7* in SCC cells.

mRNA of *MMP7* was specifically up-regulated in the invasion nests. The expression of MMP7 was enhanced under a hypoxic condition in colon cancer cells ([@R28]). Ingenuity pathway analysis associated the genomic profile of invasive SCC with Hypoxia-inducible factor 1α signaling. Thus, the microenvironment of the invasive tumor front may be prone to induce MMP7 by multiple mechanisms. We confirmed the function of MMP7 in the migration of cutaneous SCC cells. The migration of A431 cells was significantly delayed by a specific MMP7Ab in a dose dependent fashion. MMP7 has been shown to be involved in the tumor migration of various cancers through multiple pathways. One such mechanism is proposed in colon cancer cells, where MMP7 cleaves β3 chain of laminin332, resulting in enhancing migration capacity ([@R28]). Laminin332 can be processed by various enzymes and its remodeling has been implicated in SCC migration ([@R19]). All subunits of laminin332 were significantly up-regulated along with SCC progression ([Table S4](#SD1){ref-type="supplementary-material"}). Taken together, these results may suggest a function of MMP7 in SCC migration via accelerating laminin332 remodeling. In addition, it has been demonstrated that MMP7 shed E-cadherin and released an 80-kDa fragment of E-cadherin from A431 cells, which would facilitate an epithelial-to-mesenchymal transition like process ([@R35]). MMP7 also sheds pro heparin binding epidermal growth factor (proHB-EGF) to yield mature HB-EGF ([@R10]). Overall, MMP7 enhances proliferation, migration, and invasion of cancer cells ([@R13]). However, we acknowledge that the effect of blockade of MMP7 in 0.1%FBS-containing media was partially diminished in the 10%FBS-containing media, indicating the contribution of other factors to the migration of A431 cells. There was a discrepancy between the expression of *IL-24* and *MMP7* in the two SCC cell lines tested. It should be noted that strong expression of *MMP7* was observed in the aggressive A431 cells. Whereas the less aggressive SCC13 cells and HaCaT cells, immortalized keratinocytes, had only weak or absent expression of MMP7. This observation may support an important role of MMP7 in SCC migration. The function of IL-24 or MMP7 needs to be conclusively demonstrated using appropriate *in vivo* models. However, current mouse models of SCC do not properly recapitulate human SCC, because mouse SCCs feature follicular differentiation. Therefore, development of the animal models that accurately represent invasion of human SCC is needed.

In summary, we characterized gene expression profiling of invasion front of SCC compared to laser captured AK and SCC that have not invaded the dermis. We suggest a pro-oncogenic role of IL-24 in cutaneous SCC, unlike other cancer types, via inducing *MMP7* expression in cancer cells. Further elucidation of mechanisms governing regulation of invasion by SCC will allow for development of targeted therapy for aggressive disease not amenable to conventional intervention.

Materials and Methods {#S10}
=====================

The detailed protocols and statistical analysis are described in the SMM.

Patients and Samples {#S11}
--------------------

Institutional review board (The Rockefeller University and Weill Cornell Medical College) approval and written informed consent were obtained before enrolling patients to participate in this study. The study was performed in adherence with the Declaration of Helsinki Principles. Cutaneous SCC samples were obtained from debulking during Mohs micrographic surgery. All tumors were obtained from sun-exposed skin.

LCM {#S12}
---

Eight SCC tissues were subjected to LCM following the manufacturer's protocol for CellCut system (Molecular Machines and Industries, Haslett, MI). Normal skin samples used in this study (n=10) as a reference came from our previous study ([@R18])

RNA extraction and quantification {#S13}
---------------------------------

RNA extraction was performed using RNeasy Kit (QIAGEN, Valencia, CA).

RNA amplification and hybridization {#S14}
-----------------------------------

Total RNA was subjected to two-cycle cDNA synthesis (Affymetrix, Santa Clara, CA), with a slight modification described previously ([@R20]). Human Genome U133 A2.0 arrays (Affymetrix) were used. The data have been deposited to the Gene Expression Omnibus repository (GSE42677).

Cell culture {#S15}
------------

A431 cells were purchased from ATCC. SCC13 cells were kindly provided by professor Rheinwald (Harvard Medical Center, MA). Cells were grown in appropriate media. When they reached 80% confluence, the cells were starved in empty media for 24 hours, followed by stimulation with various cytokines at indicated concentrations for 24 hours.

Scratch assay {#S16}
-------------

A431 cells were grown in a 10%FBS-containing media. When the cells reached 90% confluence, a wound was made by tip of a 200µl pipet tip and the media was replaced with either 0.1%- or 10%FBS-containing media. The MMP7Ab was purchased from R&D systems and added to the culture media at the indicated concentrations. The wounds were photographed every 12 hours up to 36 hours. Measurement of wound area and calculation of percent wound closure are described in the SMM.

Quantitative RT-PCR {#S17}
-------------------

Pre-amplification quantitative RT-PCR technique was used for measuring mRNA expression values in total RNA extracted from microdissected samples according to the company's instruction (Applied Biosystems, Foster City, CA). Regular TaqMan RT-PCR method was used to detect the signals in total RNA extracted from cultured cells. All data were normalized to RPLP0/hARP. Primers and probes used in this experiment are listed in [Table S7](#SD1){ref-type="supplementary-material"}.

Immunohistochemistry {#S18}
--------------------

Frozen skin sections were prepared and standard procedures were used. Antibodies used in this experiment are listed in [Table S8](#SD1){ref-type="supplementary-material"}.

Statistical analysis {#S19}
--------------------

Microarray data were analyzed using R/Bioconductor packages ([www.r-project.org](http://www.r-project.org)). The Harshlight package ([@R36]) was used to scan Affymetrix chips for spatial artifacts. Expression values were obtained using gcrma algorithm. Expression values were linearly modeled in the *limma* package framework. For the comparison of interest, the moderated t-test was used to assess differential expression. P-values for each comparison were adjusted for multiple hypotheses using the Benjamini-Hochberg approach. Genes with FDR\<0.05 and FCH\>3.0 were considered as differentially expressed.

Statistical analysis of all RT-PCR data was performed using Graphpad Prism ver.5 (GraphPad Software, La Jolla, CA). A *p*\<0.05 was considered as statistically significant.

Supplementary Material {#SM}
======================
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![Combined LCM and cDNA microarray analysis identified region specific gene expression changes in the SCC tissues\
(a) Images of H&E staining for each region and number of differentially expressed probe-sets identified in the corresponding regions compared to normal epidermis. Top panels; lower magnification, middle panels; higher magnifications, bottom panels; images of LCM. Scale bar=100µm. (b) A Venn-Diagram revealed the numbers of commonly regulated probe-sets among the dysplasia/cancer regions compared to normal epidermis as well as uniquely regulated probe-sets in the SCC invasion nests. (c) The top 10 up- and down-commonly regulated probe-sets among the three dysplasia/cancer regions compared to normal epidermis are listed. The numbers in red indicate up-regulated probe-sets whereas those in green indicate down-regulated probe-sets.](nihms542467f1){#F1}

![Mapping the regional expression differences of known MMPs was performed by RT-PCR and immunohistochemistry\
(a) A heat map of mean expression of all MMPs tested across the regions was shown. (b--e) RT-PCR was performed for (b) MMP1, (c) MMP3, (d) MMP7, and (e) MMP10 (n=5 for each region). Y-axis shows relative expression level of each gene compared to the housekeeping gene RPLP0/hARP in Log~2~ (mean ± SEM). A *p*-value was estimated among four keratinocytic regions (One-way ANOVA with Tukey's correction). The resultant *p* values were shown in parentheses. A line between tow bars; statistical significance between two cell types. (f--m) Corresponding protein product was detected by IHC for (f--g) MMP1, (h--i) MMP3, (j--k) MMP7, (l--m) MMP10. Upper panels; normal skin, lower panels; SCC. Dotted lines; borders between epidermis/tumor nests and dermis. Scale bar=100µm.](nihms542467f2){#F2}

![IL-24 induced the expression of MMP7 in HaCaT and A431 cells\
(a--c) IL24 expression was examined at the mRNA level (a) and at the protein level in (b) normal skin and (c) SCC. Scale bar=100µm. (d-f) mRNA expression of (d) IL20R1, (e) IL20R2, and (f) IL22R1 was examined. (g) Expression levels of IL-24 mRNA in SCC13 cells after a twelve hour treatment with PBS or indicated cytokines are shown. AA; acidic acetate. (h-j) Expression of MMP7 mRNA in the three cell lines was evaluated after a 24 hour treatment with PBS, IL24 (40ng/ml and 100ng/ml), or IL20 (100ng/ml). Relative expression compared to RPLP0/hARP in Log~2~ is shown for all RT-PCR results (mean ± SEM). A line between two bars; statistical significance between the two conditions (one-way ANOVA with Tukey's correction). \*\*\*; *p*\<0.0001 against both PBS and AA (repeated measures ANOVA with Tukey's correction).](nihms542467f3){#F3}

![Blocking of MMP7 delayed the migration of A431 cells\
Scratch was made on a culture of A431 cells at 90% confluence and cells were cultured in 0.1%FBS-containing media with or without indicated concentrations of anti-MMP7 antibody (MMP7Ab) for 36 hours. Cells were photographed every 12 hours. (a--d) Representative images of area after a 36 hour cultivation with (a) PBS, (b) 20ng/ml of MMP7Ab, (c) 200ng/ml of MMP7Ab, and (d) 2000ng/ml of MMP7Ab. Two white dotted lines depict the initial area. (e) The bar graph shows mean of percent wound closure for each treatment after 36 hours. (f) The graph depicts the chronological change of the percent wound closure for each condition. An error bar shows S.E.M. (n=3). \*\*; *p*\<0.01 between MMP7Ab2000 vs. PBS and MMP7Ab20 for a 24H treatment, and between MMP7Ab2000 vs. PBS, MMP7Ab20, and MMP7Ab200 for a 36H treatment (repeated measures ANOVA with Tukey's correction).](nihms542467f4){#F4}

###### 

Selected up- and down-regulated SCC invasion signature genes

  a\. Selected up-regulated SCC invasion signature genes                                                               
  -------------------------------------------------------- ------ --------- ------ --------- ----------- ------------- ---------------------------------------------------------------------
  MMP12                                                    1.14   0.90      2.31   0.37      **32.97**   **\< 0.01**   matrix metallopeptidase 12
  PTHLH                                                    0.76   0.67      3.09   0.05      **17.89**   **\< 0.01**   parathyroid hormone-like hormone
  MMP3                                                     1.19   0.89      4.77   0.15      **16.38**   **\< 0.01**   matrix metallopeptidase 3
  AIM2                                                     1.80   0.34      2.72   0.08      **14.61**   **\< 0.01**   absent in melanoma 2
  NEFL                                                     0.87   0.83      2.23   0.13      **13.34**   **\< 0.01**   neurofilament, light polypeptide
  MMP13                                                    0.96   0.95      2.37   0.11      **12.53**   **\< 0.01**   matrix metallopeptidase 13
  KRT19                                                    1.17   0.78      2.80   0.02      **11.33**   **\< 0.01**   keratin 19
  INHBA                                                    0.86   0.80      2.42   0.07      **10.89**   **\< 0.01**   inhibin, beta A
  IL7R                                                     1.62   0.36      2.86   0.03      **9.45**    **\< 0.01**   interleukin 7 receptor
  CXCL10                                                   3.63   0.24      5.26   0.11      **9.44**    **0.02**      chemokine (C-X-C motif) ligand 10
  SPP1                                                     1.45   0.70      2.18   0.37      **8.76**    **\< 0.01**   secreted phosphoprotein 1
  PLAU                                                     2.60   \< 0.01   2.73   \< 0.01   **8.45**    **\< 0.01**   plasminogen activator, urokinase
  PDPN                                                     0.41   0.01      2.11   0.03      **8.04**    **\< 0.01**   podoplanin
  KRT18                                                    2.24   0.16      2.80   0.06      **7.69**    **\< 0.01**   keratin 18
  FN1                                                      0.67   0.61      3.30   0.09      **7.06**    **\< 0.01**   fibronectin 1
  APOBEC3G                                                 2.45   0.03      2.55   0.02      **6.96**    **\< 0.01**   apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
  LAMC2                                                    0.79   0.69      1.17   0.77      **6.77**    **\< 0.01**   laminin, gamma 2
  IL24                                                     1.20   0.79      2.03   0.23      **6.74**    **\< 0.01**   interleukin 24
  CXCR4                                                    2.60   0.09      1.78   0.31      **6.16**    **\< 0.01**   chemokine (C-X-C motif) receptor 4
  MMP7                                                     1.09   0.89      1.16   0.77      **5.43**    **\< 0.01**   matrix metallopeptidase 7

  b\. Selected down-regulated SCC invasion signature genes                                                              
  ---------------------------------------------------------- ------ --------- ------ --------- ---------- ------------- ---------------------------------------------------------------
  TYRP1                                                      0.79   0.88      0.45   0.54      **0.03**   **\< 0.01**   tyrosinase-related protein 1
  FLG                                                        0.60   0.70      0.14   0.09      **0.04**   **\< 0.01**   filaggrin
  LOR                                                        1.39   0.80      0.25   0.21      **0.07**   **0.01**      loricrin
  TFAP2B                                                     1.17   0.83      0.36   0.10      **0.07**   **\< 0.01**   transcription factor AP-2 beta
  HPGD                                                       0.41   0.18      0.29   0.05      **0.08**   **\< 0.01**   hydroxyprostaglandin dehydrogenase
  DCT                                                        1.24   0.81      0.31   0.11      **0.08**   **\< 0.01**   dopachrome tautomerase
  NFIB                                                       0.61   0.38      0.36   0.04      **0.10**   **\< 0.01**   nuclear factor I/B
  CYorf15B                                                   0.40   0.38      0.23   0.12      **0.11**   **0.02**      chromosome Y open reading frame 15B
  DDAH1                                                      1.18   0.74      0.73   0.50      **0.12**   **\< 0.01**   dimethylarginine dimethylaminohydrolase 1
  CHI3L1                                                     0.76   0.73      0.33   0.11      **0.12**   **\< 0.01**   chitinase 3-like 1
  LCE2B                                                      1.15   0.87      0.25   0.05      **0.13**   **\< 0.01**   late cornified envelope 2B
  ANXA9                                                      1.17   0.81      0.54   0.26      **0.13**   **\< 0.01**   annexin A9
  NEB                                                        1.06   0.90      0.41   0.02      **0.13**   **\< 0.01**   nebulin
  ALOX12                                                     1.26   0.47      0.38   \< 0.01   **0.14**   **\< 0.01**   arachidonate 12-lipoxygenase
  CEP76                                                      0.46   0.09      0.40   0.04      **0.14**   **\< 0.01**   centrosomal protein 76kDa
  ACSBG1                                                     0.93   0.89      0.38   0.02      **0.15**   **\< 0.01**   acyl-CoA synthetase bubblegum family member 1
  KIT                                                        0.64   0.43      0.42   0.09      **0.16**   **\< 0.01**   v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
  NFASC                                                      0.38   \< 0.01   0.36   0.00      **0.16**   **\< 0.01**   neurofascin homolog
  AADAC                                                      1.34   0.54      0.47   0.08      **0.16**   **\< 0.01**   arylacetamide deacetylase
  ATP6V0E2                                                   0.80   0.55      0.38   0.00      **0.17**   **\< 0.01**   ATPase, H+ transporting V0 subunit e2

###### 

MMP expression across regions measured by cDNA microarray analysis

  Symbol   AK         SCC in situ   SCC invasion                         
  -------- ---------- ------------- -------------- -------- ------------ --------
  MMP9     **3.42**   0.03          **3.85**       0.01     **19.31**    \<0.01
  MMP11    **3.05**   \<0.01        **5.57**       \<0.01   **5.77**     \<0.01
  MMP14    **3.08**   \<0.01        **4.06**       \<0.01   **3.91**     \<0.01
  MMP1     1.28       0.87          **16.61**      0.02     **107.82**   \<0.01
  MMP2     1.05       0.93          **5.85**       \<0.01   **10.50**    \<0.01
  MMP10    1.14       0.89          **7.21**       \<0.01   **48.35**    \<0.01
  MMP3     1.19       0.89          4.77           0.15     **16.38**    \<0.01
  MMP7     1.09       0.89          1.16           0.77     **5.43**     \<0.01
  MMP12    1.14       0.90          2.31           0.37     **32.97**    \<0.01
  MMP13    −1.04      0.95          2.37           0.11     **12.53**    \<0.01
  MMP17    2.62       \<0.01        2.81           \<0.01   **3.50**     \<0.01
